Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phlow Partners With USP On Continuous Manufacturing

Alliance To Validate Production Processes Could Be ‘Catalyst For Industry Change’

Executive Summary

Phlow Corp has announced a strategic alliance with the US Pharmacopeia to certify and validate continuous manufacturing processes as it aims to bolster US supplies of essential medicines. The company believes the move could serve as a catalyst for wider generics industry adoption of continuous manufacturing.

You may also be interested in...



Phlow Enters Deal To Expand CDMO Services With Continuous Manufacturing

Phlow partners to provide continuous manufacturing research and development services for active pharmaceutical ingredients and registered starting materials. The company has also announced the appointment of Malcolm Berry as a senior consultant at the company’s R&D team. 

FDA Seeks Feedback On Continuous Manufacturing

A draft ICH guidance on continuous manufacturing has been opened up for comment by the FDA, as continuous manufacturing becomes an increasingly prominent topic for the generics industry.

Premier Invests In Exela To Procure Shortage-Hit Generic Injectables

As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel